CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* 1\. Age ≥18 years old, gender unlimited;
* 2\. Abnormal B cell immunotyping was CD19 positive;
* 3\. Patients diagnosed with B-cell acute lymphoblastic leukemia by histological or immunotyping;
* 4\. Meets the diagnosis of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and includes any of the following conditions:

  1. No CR was obtained after standard chemotherapy;
  2. CR was induced for the first time, but the duration of CR was less than 12 months;
  3. R/R B-ALL that does not work after the first or more remedial treatments;
  4. Two or more relapses;
* 5\. The researchers believed that the patient had been adequately treated, such as auto-HSCT, auto-CART could not be prepared or preparation failed. Autologous CAR-T preparation failure was defined as including too few autologous lymphocytes (\<1×109) or insufficient expansion during preparation or failure to meet the release criteria;
* 6\. Total bilirubin ≤51 ( μmol/L), alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal, creatinine ≤176.8 (μmol/L);
* 7\. Absolute neutrophil count: ≥ 0.5×109/L; Platelet: ≥ 30×109/L; Hemoglobin ≧60g/L;
* 8\. Echocardiography showed left ventricular ejection fraction (LVEF) ≥40%;
* 9\. The estimated survival is more than 3 months;
* 10\. ECOG score 0-2;
* 11\. Women and men who are fertile must consent to the use of appropriate contraception before entering the study, during study participation, and for 6 months after transfusion (the safety of this therapy for the unborn child is not known, with unknown risks);
* 12\. Subjects who are willing to participate in the study are able to understand and have the ability to sign informed consent.

Exclusion Criteria:

* 1\. Known allergies to research preconditioning measures, etc;
* 2\. People with a history of epilepsy or other central nervous system disorders;
* 3\. People with a history of prolonged QT or severe heart disease;
* 4\. Less than 100 days after receiving allogeneic hematopoietic stem cell transplantation;
* 5\. Hiv-infected person;
* 6\. Persons with active hepatitis B or C virus; Those who are not cured have active infections;
* 7\. Insufficient amplification ability (\< 5x) in response to CD3 / CD28 costimulatory signals;
* 8\. Combined use of systemic steroids (e.g., prednisone ≥20mg) within 3 days prior to screening, except for ongoing or intermittent use of topical, inhaled or intranasal steroids within 2 weeks or at present; Or have systemic diseases that require long-term use of immunological agents;
* 9\. Patients who received anti-cancer chemotherapy or other drugs within 2 weeks prior to screening;
* 10\. Any situation that the investigator believes may increase the risk of the subjects or interfere with the study results.

主要终点：Dose-limiting toxicity (DLT) · Adverse events assessed according to NCI-CTCAE v5.0 criteria · Up to 28 days after Treatment；Incidence of treatment-emergent adverse events (TEAEs) · Incidence of treatment-emergent adverse events \[Safety and Tolerability\] · Up to 2 years after Treatment
次要终点：Duration of remission ,DOR；Overall survival, OS；Event-free survival (EFS)

• Administration of CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells · EXPERIMENTAL · Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.

A Clinical Study on the Safety and Effectiveness of donor derived CD19 CAR-T Cells in the treatment of R/R B-cell acute lymphoblastic leukemia